High-throughput Screening Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI Automation and Asia-Pacific Growth Drive a USD 45.07 Billion Opportunity
Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "High-throughput Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global high-throughput screening market is estimated at USD 28.23 billion in 2026, up from USD 25.71 billion in 2025. The market is projected to reach USD 45.07 billion by 2031, expanding at a CAGR of 9.81% during 2026-2031. Growth is being driven by advances in laboratory automation, robotic liquid-handling systems, high-content imaging, artificial intelligence, cell-based assays and expanding pharmaceutical and biotechnology research pipelines.
Robotic Automation and Imaging Improve Screening Performance
Adaptive robotics are increasing throughput, reproducibility and data quality across drug discovery workflows. Computer-vision modules can guide pipetting accuracy in real time, reducing experimental variability by 85% compared with manual processes. Integrated AI detection algorithms can process more than 80 slides per hour, raising the capacity of high-content imaging systems and supporting faster analysis of complex biological responses.
Dual-interface programming also enables researchers to configure sophisticated workflows without specialist coding expertise. Although capital investments can exceed USD 2 million per workcell, improving return-on-investment profiles make automation increasingly attractive for laboratories screening more than 100,000 compounds annually. These capabilities are accelerating platform upgrades and strengthening demand for scalable high-throughput screening technologies.
Pharmaceutical and Biotechnology R&D Spending Supports Market Growth
Rising investment in precision medicine and drug discovery is directing more funding toward screening platforms that combine computational biology with automated experimentation. AI-powered discovery processes have reduced candidate identification timelines from approximately six years to less than 18 months. This improvement allows pharmaceutical and biotechnology companies to evaluate compounds earlier, reduce development risk and prioritize promising candidates more efficiently.
Oncology and rare-disease pipelines are among the leading beneficiaries. Rapid compound triage supports combination-therapy research, personalized treatment development and the analysis of complex disease pathways. Cell-based models, organoids and predictive analytics are also enabling research teams to generate more clinically relevant data during the early stages of development.
Capital Costs Remain a Key Adoption Barrier
Fully automated high-throughput screening workcells can require initial investments approaching USD 5 million when software, validation and training are included. Annual maintenance and licensing expenses may increase operating budgets by 15-20%, creating financial challenges for smaller biotechnology companies and research institutions.
While high-volume laboratories can achieve favorable total ownership costs, capital intensity continues to support demand for outsourced screening services, equipment leasing and shared research facilities. Technology obsolescence also remains a concern as automation, imaging and analytics platforms evolve rapidly. Additional market constraints include a shortage of skilled assay-automation specialists and the need to integrate new systems with established laboratory infrastructure.
Cell-Based Assays Lead Technology Adoption
Cell-based assays accounted for 44.63% of the high-throughput screening market in 2025. Their leading position reflects the ability to model complex signaling pathways and predict human efficacy more accurately than many biochemical alternatives. Advances in fluorescent reporters, 3-D culture scaffolds and label-free impedance technologies are improving the detection of subtle phenotypic changes.
Lab-on-a-chip and microfluidic platforms are forecast to expand at a 10.54% CAGR, supported by lower reagent requirements, enhanced assay sensitivity and improved workflow efficiency. High-content imaging combined with AI-driven analytics is also increasing the amount and quality of data generated per screen. Organoid-based screening provides additional insight into tissue structure and tumor-microenvironment responses, making it especially valuable for oncology research.
Toxicology and ADME Applications Gain Momentum
Primary and secondary screening represented 52.98% of the market in 2025, confirming their central role in hit identification and lead selection. Automated assay miniaturization and AI-based triage are helping discovery teams process more samples while reducing unnecessary laboratory testing.
Toxicology and ADME applications are expected to grow at a 13.41% CAGR through 2031 as regulators and drug developers increase their focus on non-animal safety data. Human-derived cell lines, organ-on-chip devices and predictive AI models enable broader safety profiling before candidates enter later development stages. CRISPR-enabled target validation and multiplexed biomarker analysis further strengthen disease-gene research and translational relevance.
Regional High-throughput Screening Market Outlook
North America generated 39.22% of global revenue in 2025. Its leadership is supported by established pharmaceutical ecosystems, strong venture capital participation, extensive compound libraries and rapid adoption of AI-enabled automation. In the United States, National Institutes of Health grants continue to encourage translational research partnerships between academic institutions and industry.
Europe is experiencing steady growth as stringent quality standards and supportive regulatory frameworks encourage the use of 3-D cell cultures and next-generation toxicology platforms. Research clusters in Germany, the Netherlands and Scandinavian countries are also investing in sustainable laboratory technologies, including reusable microfluidic cartridges.
Asia-Pacific is projected to record the fastest regional growth at a 13.74% CAGR. Renewed biotechnology investment in China, supportive government policies and licensing partnerships between Western pharmaceutical companies and Asian biotechnology firms are expanding regional screening capacity. Competitive operating costs and rapid adoption of organ-on-chip and microfluidic technologies are further strengthening the region's role in global drug discovery.
South America and the Middle East & Africa offer longer-term growth opportunities. Brazil and the United Arab Emirates are supporting shared high-throughput screening facilities within biotechnology parks. Although infrastructure limitations and regulatory differences currently restrict adoption, expansion by global contract development and manufacturing organizations is expected to promote technology transfer, workforce development and local research capacity.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advances in Robotic Liquid-Handling & Imaging Systems
4.2.2 Rising Pharma/Biotech R&D Spending & Pipeline Growth
4.2.3 Adoption of Physiologically Relevant Cell-Based & 3-D Assays
4.2.4 AI/ML In-Silico Triage Shrinking Wet-Lab Library Size
4.2.5 Venture-Backed Microfluidic uHTS Platforms
4.2.6 Rising CDMOs Bundling HTS In Integrated Discovery Contracts
4.3 Market Restraints
4.3.1 High Capital Expenditure for Fully Automated HTS Workcells
4.3.2 Shortage of Skilled Assay-Automation Specialists
4.3.3 Data-Quality & Reproducibility Issues Across Labs
4.3.4 Sustainability Push Against Single-Use 1536-Well Plastics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitutes
4.4.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value in USD)
5.1 By Technology
5.1.1 Ultra-high-throughput Screening (uHTS)
5.1.2 Cell-based Assays
5.1.3 Lab-on-a-chip / Microfluidics
5.1.4 Label-free Technologies
5.1.5 High-content Screening
5.2 By Application
5.2.1 Target Identification / Validation
5.2.2 Primary & Secondary Screening
5.2.3 Toxicology & ADME
5.3 By Product & Service
5.3.1 Instruments
5.3.2 Reagents, Kits & Consumables
5.3.3 Software & Informatics
5.3.4 Services
5.4 By End-user
5.4.1 Pharma & Biotech Firms
5.4.2 Contract Research / CDMOs
5.4.3 Academic & Research Institutes
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Thermo Fisher Scientific
6.3.2 PerkinElmer (Revvity)
6.3.3 Danaher (Molecular Devices)
6.3.4 Agilent Technologies
6.3.5 Merck KGaA (Sigma-Aldrich)
6.3.6 Beckman Coulter (Life Sciences)
6.3.7 Tecan Group
6.3.8 GE Healthcare (Cytiva)
6.3.9 Axxam SpA
6.3.10 Bio-Rad Laboratories
6.3.11 Hamilton Company
6.3.12 Promega Corporation
6.3.13 Corning Life Sciences
6.3.14 HighRes Biosolutions
6.3.15 Charles River Labs
6.3.16 Eurofins Discovery
6.3.17 Evotec SE
6.3.18 Abcam plc
6.3.19 DiscoverX (Crownbio)
6.3.20 Labcyte (Echo) - Beckman
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/ckx9du
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.